Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 10/29/26
Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It MattersThe Motley Fool • 10/27/26
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockMarketBeat • 10/26/26
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 10/26/26
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 StudyBusiness Wire • 10/26/26
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?The Motley Fool • 10/25/26
Buy 8 Barron's Big Better Bets (Than T-Bills) Out Of 14 'Safer' October DiviDogsSeeking Alpha • 10/25/26
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 10/23/26
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?Zacks Investment Research • 10/23/26
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026Business Wire • 10/23/26
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology PipelineBusiness Wire • 10/23/26
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological ConditionsBusiness Wire • 10/23/26
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 StudyBusiness Wire • 10/23/26